Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 4/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 4/20 | 1.00 |
| ▸ | BCR | P11274 | 4/20 | 1.00 |
| ▸ | ESR1 | P03372 | 11/20 | 0.74 |
| ▸ | ESR2 | Q92731 | 11/20 | 0.74 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.72 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3014459 | 0.95 | ABL1 (0.91) | ABL1ABCB1BCRESR1ESR2 | |
| SCHEMBL3016969 | 0.91 | ABL1 (0.83) | ABL1ABCB1BCRESR1ESR2 | |
| SCHEMBL8536612 | 0.90 | ABL1 (0.82) | ABL1ABCB1BCRESR1ESR2 | |
| SCHEMBL5425451 | 0.90 | ESR2 (0.90) | ABL1ABCB1BCRESR1ESR2 | |
| SCHEMBL30275026 | 0.90 | ESR2 (0.90) | ABL1ABCB1BCRESR1ESR2 | |
| SCHEMBL3015072 | 0.86 | ABL1 (0.74) | ABL1ABCB1BCRESR1ESR2 | |
| SCHEMBL29991899 | 0.85 | ESR1 (1.00) | ABL1ABCB1BCRESR1ESR2 | |
| SCHEMBL2699234 | 0.85 | ESR1 (1.00) | ABL1ABCB1BCRESR1ESR2 | |
| SCHEMBL2124794 | 0.84 | ESR1 (1.00) | ABL1ABCB1BCRESR1ESR2 | |
| Methane SCHEMBL5526746 | 0.83 | ESR1 (0.95) | ABL1ABCB1BCRESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835659-B2 | Polysubstituted benzofurans and medicinal applications thereof | IKERCHEM, S.L. (ES) | 2014-09-16 | — | — | US | disclosed |
| US-20130217730-A1 | POLYSUBSTITUTED BENZOFURANS AND MEDICINAL APPLICATIONS THEREOF | IKERCHEM, S.L. (ES) | 2013-08-22 | — | — | US | disclosed |
| EP-2569292-A1 | POLYSUBSTITUTED BENZOFURANS AND MEDICINAL APPLICATIONS THEREOF | Ikerchem, S.L. (ES) | 2013-03-20 | — | — | EP | disclosed |
| EP-2388255-A1 | Polysubstituted benzofurans and medicinal applications thereof | Ikerchem, S.L. (ES) | 2011-11-23 | — | — | EP | disclosed |
| WO-2011141458-A1 | POLYSUBSTITUTED BENZOFURANS AND MEDICINAL APPLICATIONS THEREOF | IKERCHEM, S.L. (ES) | 2011-11-17 | — | — | WO | disclosed |
| US-8038466-B1 | Power receptacle with enlarged heat dissipation path formed on mating face and power connector assembly thereof | ALLTOP ELECTRONICS (SUZHOU) CO., LTD (CN) | 2011-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217730-A1 | POLYSUBSTITUTED BENZOFURANS AND MEDICINAL APPLICATIONS THEREOF | AGER, TFEB, FPGS | ABL1 4352/4885ABCB1 279/4885BCR 2832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.